leisure time -WSS

leisure time

author：explore 2025-10-06 19:20:41 - browse：39

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Websites selling Wegovy, Zepbound ingredients targeted by FDA

hotspot

focus

WSS

Juul documents reveal insider tactics on political lobbying

Lilly’s weekly insulin works as well as daily products, new studies show

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

CVS is willing to dump 10% of its Medicare Advantage members

Abbott's new stent may help patients with peripheral artery disease

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

hotspot

leisure time

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

Having children helps parents live longer, especially after age 80

Dobbs anniversary: the lost opportunity of abortion as health care

Ebola vaccine can save some who are already sick, per new study

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Long Covid research funding gets a major boost from NIH

How one medical school became remarkably diverse

Resistance to opioid

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Wikipedia

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Congress might make insulin pumps more accessible to the blind

Galapagos to make CAR

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Too many hospitalized Covid

Report cites 'urgent' need to recruit more diverse clinical trial participants

Wikipedia

hotspot

focus

focus